ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) had its target price raised by HC Wainwright from $50.00 to $53.00 in a research report released on Monday morning, The Fly reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
Separately, Guggenheim began coverage on shares of ANI Pharmaceuticals in a report on Tuesday, February 28th. They issued a buy rating and a $55.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $52.00.
ANI Pharmaceuticals Stock Performance
Shares of ANIP stock opened at $41.01 on Monday. The firm’s 50 day moving average price is $43.06 and its 200-day moving average price is $39.10. The company has a debt-to-equity ratio of 0.91, a quick ratio of 2.40 and a current ratio of 3.46. ANI Pharmaceuticals has a one year low of $22.31 and a one year high of $45.99. The firm has a market cap of $716.44 million, a P/E ratio of -13.49 and a beta of 1.06.
Institutional Investors Weigh In On ANI Pharmaceuticals
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is a bio-pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.
- Get a free copy of the StockNews.com research report on ANI Pharmaceuticals (ANIP)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.